Methods for obtaining an extract enriched in rosmarinic acid from fresh plant material selected from the fresh aerial parts, flowering tops, flowers and/or leaves of plants from the family Lamiaceae, Araliaceae, Boraginaceae, Apiaceae, Poaceae and Malvaceae. The methods include steam bleaching the plant material followed by continuous expression with at least one compression screw, under pressure of between 4 and 10 bar from which the sap (liquid co-product) is recovered. Then, the sap is filtered to produce a clarified sap and is subsequently atomized to obtain a granulated or finely powdered extract containing at least 5% of rosmarinic acid in weight relative to the total weight of the extract. Compositions having such an extract as an active agent are disclosed. The compositions are used in the food, cosmetic, nutraceutical and pharmaceutical fields.

A composition and method for treatment of brittle, broken, cracked or otherwise damaged nail and hoof plates. The composition is an aqueous-organic medium containing a non-covalent complex of a diamine and an organic acid or an aqueous-organic medium with a diamine alone.

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/′ receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/′ receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

A method of treating a fungal infection of the nails is disclosed herein. In one embodiment, the treatment method comprises applying a formulation directly to a nail, wherein the formulation comprises bleaching and moisturizing agents to improve cosmetic appearance of the nail. In another embodiment, the treatment method comprises a formulation applied directly to a nail, wherein the formulation is subsequently exposed to a light source to improve efficacy of the formulation applied to the nail.

A method of treating a fungal infection of the nails is disclosed herein. In one embodiment, the treatment method comprises applying a formulation directly to a nail, wherein the formulation comprises bleaching and moisturizing agents to improve cosmetic appearance of the nail. In another embodiment, the treatment method comprises a formulation applied directly to a nail, wherein the formulation is subsequently exposed to a light source to improve efficacy of the formulation applied to the nail.

It relates to a combination comprising a) rhamnose or a rhamnose-rich polysaccharide; b) a film-forming agent; and c) one or more further active agents selected from: i) a hyaluronic acid derivative selected from the group consisting of hyaluronic acid, a pharmaceutically or cosmetically acceptable salt thereof, and a cationized hyaluronic acid, ii) a silanol compound, and iii) an extract of Pistacia lentiscus; for use in the treatment and/or prevention of fungal infections in human beings. It also relates to this combination per se, and to pharmaceutical or cosmetic topical nail composition containing it.

A balanced formulation based on amino acids, which finds application in the field of functional and antiaging medicine, and in the cosmetic field for the well-being of hair, skin and nails is provided.

The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide and/or peptide derivative antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity are described. Also described are peptide and/or peptide derivative antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple γc-cytokine family members.

The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide and/or peptide derivative antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity are described. Also described are peptide and/or peptide derivative antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple γc-cytokine family members.